Adamas Pharmaceuticals, Inc. (ADMS) |
|
8.22 0 (0%)
|
12-31 19:00 |
|
Open: |
8.24 |
Pre. Close: |
8.22 |
|
High:
|
8.25 |
Low:
|
8.18 |
|
Volume:
|
3,151,400 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-01-28 4:23:49 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 9.63 One year: 11.25 |
| Support: |
Support1: 8.2 Support2: 8.18 |
| Resistance: |
Resistance1: 8.25 Resistance2: 9.63 |
| Pivot: |
8.22 |
| Moving Average: |
MA(5): 8.22 MA(20): 8.22
MA(100): 7.42  MA(250): 6.04 |
| MACD: |
MACD(12,26): 0.01  Signal(9): 0.01 |
| Stochastic oscillator: |
%K(14,3): 57.14 %D(3): 57.14 |
| RSI: |
RSI(14): 73.52 |
| 52-week: |
High: 8.25 Low: 4.01 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
|
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
- |
- |
|
Low:
|
- |
- |
|
Close:
|
- |
- |
|
Company Description |
|
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California. |
Headline News |
Sat, 01 Apr 2023
Tazeen Ahmad's Stock Ratings - Benzinga
Wed, 24 Nov 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas ... - GlobeNewswire
Mon, 11 Oct 2021
Supernus bolsters Parkinson's portfolio with $400 mln deal for ... - Reuters
Mon, 09 Aug 2021
Adamas Reports Second Quarter 2021 Financial Results - Business Wire
Thu, 22 Jul 2021
Adamas Announces Issuance of New Patents for GOCOVRI and ... - Business Wire
Mon, 01 Mar 2021
Adamas Pharmaceuticals Announces Closing of Public Offering of ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
46 (M) |
| Shares Float |
31 (M) |
|
% Held by Insiders
|
1.7 (%) |
|
% Held by Institutions
|
80.3 (%) |
|
Shares Short
|
1,600 (K) |
|
Shares Short P.Month
|
2,510 (K) |
Stock Financials |
|
EPS
|
-1.61 |
|
EPS Est Next Qtl
|
-1.17 |
|
EPS Est This Year
|
-3.77 |
|
EPS Est Next Year
|
-3.43 |
|
Book Value (p.s.)
|
-0.1 |
|
Profit Margin (%)
|
-66.82 |
|
Operating Margin (%)
|
-45.14 |
|
Return on Assets (ttm)
|
-16.4 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
16.89 |
|
Gross Profit (p.s.)
|
1.58 |
|
Sales Per Share
|
1.8 |
|
EBITDA (p.s.)
|
-0.81 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-51 (M) |
|
Levered Free Cash Flow
|
-29 (M) |
Stock Valuations |
|
PE Ratio
|
-5.14 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-91.34 |
|
Price to Sales
|
4.55 |
|
Price to Cash Flow
|
-0.01 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
